Novo Nordisk Says More To Victoza Outcomes Benefit Than A GLP-1 Class Effect

Novo Nordisk's ESC satellite symposium on heels of FDA approval of CV event prevention claim for Victoza highlights differences compared to Sanofi's competing Lyxumia, which failed an outcomes study.